Astellas Pharma Obtains Approval for Funguard and Vesicare.Tokyo, Japan, Apr 21, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Astellas Pharma announced on April 20 that it had obtained additional approval for Funguard for Infusion 50mg/75mg, its proprietary candin antifungal agents antifungal agents, n.pl agents that inhibit, control, or kill fungi. The most common yeastlike fungus occurring in or near the oral cavity is C. albicans. , and manufacturing approval for Vesicare Tablet, its proprietary agent for overactive bladder (OAB OAB Ordem dos Advogados do Brasil (Brazil) OAB Offline Address Book OAB Over-Active Bladder (urology) OAB Outlook Address Book (Microsoft) OAB Ocean Affairs Board ), from the Ministry of Health, Labor and Welfare. Funguard for Infusion 50mg and Funguard for Infusion 75mg are now available in the treatment of infections including fungemia, respiratory mycosis mycosis: see fungal infection. , and gastrointestinal mycosis in pediatric patients. Funguard for Infusion (micafungin sodium), which was initially launched in December 2002, is available in the US under the trade name of Mycamine and currently waiting approval from the European Medicines Agency The European Medicines Agency (EMEA) is a European agency for the evaluation of medicinal products. Until 2004, the European Medicines Agency was known as The European Agency for the Evaluation of Medicinal Products. Roughly parallel to the U.S. . Vesicare Tablet (solifenacin succinate), which is currently available in about 20 countries worldwide, is the first approved agent for treating OAB. Tablets are available in two different dosages, 2.5mg and 5mg. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion